|Bid||10.95 x 1400|
|Ask||10.97 x 4000|
|Day's Range||10.66 - 11.28|
|52 Week Range||2.09 - 33.79|
|Beta (5Y Monthly)||1.02|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug. 10, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||13.71|
Inovio Pharmaceuticals (NASDAQ: INO) and Gilead Sciences (NASDAQ: GILD) are major competitors in the growing market for coronavirus products, making both tantalizing stock picks. Inovio's stock has soared this year thanks to its INO-4800 coronavirus vaccine project, which has so far proven effective at producing immunity in primates. In contrast, Gilead's stock has consistently struggled despite the commercialization of its antiviral drug, remdesivir, which may be effective at helping patients recover from COVID-19.
Two biotech stocks that certainly fall into that group are Inovio Pharmaceuticals (NASDAQ: INO) and VBI Vaccines (NASDAQ: VBIV). Inovio's shares are up 259% year to date after rising as much as 860% at one point. VBI Vaccines stock is up 109% after jumping as high as 347% in July.
As of now, 10 programs are involved in phase 3 studies. The Vaccines and Related Biological Products Advisory Committee will meet Oct. 22 to discuss studies that should be performed to further confirm vaccine candidates' safety and efficacy (whether pre- or post-approval). In a briefing document, the FDA emphasized that any emergency use authorization (EUA) must be supported by phase 3 data.